about
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.Attenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-α by restoring p53 functionThe importance of treating by histological subtype in advanced soft tissue sarcoma.Key messages from the BFR14 trial of the French Sarcoma Group.REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.[Metastases from cancers of unknown primary site. Data from 302 autopsies].Imatinib in the treatment of solid tumours.Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer.A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours.Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trialEffect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma GroupTrabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center series.A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stuHigh-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's)High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management.Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation.Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.Adjuvant therapy in primary GIST: state-of-the-art.Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.Epithelioid sarcoma: need for a multimodal approach to maximize the chances of curative conservative treatment.First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group studyPhase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.[Recommendations for the management of GIST patients].Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.
P50
Q27824868-32B6B3CC-8AFD-4FE3-81F3-67B033B3C3BFQ28728301-D6864C4C-13EE-4701-847B-CD2168B546ACQ30240223-9D9B2724-7134-45B6-8F2B-9C2431F1F2F2Q30245384-9EA9FCD6-A89A-4820-9EFB-732C976DE79EQ30491125-7009F5D6-0E86-42D1-A966-BFB0B9015FE3Q31149981-64D8196C-6E6F-4F27-85A5-96E7D5DC68C8Q33273344-56B80994-34E4-4AA1-94B9-031261785DC7Q33275688-C5589DB5-A965-4DD2-88BE-B427EABB3AEDQ33276494-625EB028-3575-4C52-8DDC-19D40D4D1ACBQ33331271-6E9F7F76-87CE-428E-8C88-1359D125E5C7Q33361124-A6993117-9C92-4C6E-8A00-D478524FBCD0Q33370331-72A7CAFE-45FB-452F-8363-A117C187745CQ33381641-DAA83FC8-7DCC-4629-9659-C3CFD32D5215Q33393253-38CEB52E-FA60-4410-A0E3-C7258F75747BQ33403930-37CDD109-5104-4810-848E-7D83FEACEFDFQ33408040-DDFA18E3-C4A5-4A07-8CA0-D0DDC6370BB0Q33409579-17BED881-42BC-4383-9D70-89A5A5FFAA15Q33421348-ECEF3887-9A02-4A9E-9B3E-699FA80CA26BQ33436300-E913DD7F-B345-4B58-925D-0C4AB9DE6230Q33440308-DDD0CEED-31ED-4939-8648-6EB9CF0A932BQ33447149-B855D9EA-0ADD-4F3C-A0E4-E6959B093D7CQ33488268-C2569372-16D5-4D75-98F5-3A470F9BEAEEQ33561602-25C75168-88D9-4EA5-ACE4-7D0D53AA58FFQ33648995-F5A354A0-2ABA-40AE-A6AD-EF6C9486F339Q33654843-A0F5B4FF-669B-40C0-A6B6-42B5B4330185Q33747348-93DB11AF-42C5-4904-A40D-422C4E56ABB2Q33821400-BFB5B72B-3BD7-46BA-922F-EF5E61366AA9Q34023059-A770F814-43A7-497A-98C0-BF7A2927323BQ34028152-172780A1-D047-40E2-8E05-2D18F94A1219Q34083140-8761E77E-4F4E-48C8-A598-CD548E0B21B0Q34129408-D2DE7BDC-08A2-4AD0-A639-47C3C11A3C25Q34290236-3D55B5B0-58B0-4889-A35D-9A80917A7E92Q34340390-E6022799-0986-4DF1-A53E-3CD89739CF8BQ34371963-1523F670-C56C-4C74-982E-ECC2BA8D3E29Q34413659-AB13F062-D482-4B04-AE50-8F72637AA734Q34554316-00DE0B9D-C653-44A0-8BFC-039F181328C6Q34560089-2B17F01C-032E-4BC8-B028-60989775BF2CQ34562308-B6A4EBCE-6D05-4CB0-A16D-413B4F80CBBAQ34578850-60A24FA0-972F-499F-BDFC-3A8ED964C260Q34579364-2908A81F-3ECF-4E7A-931A-C0C92DA66126
P50
description
médecin, cancérologue
@fr
oncólogu francés
@ast
عالم أورام فرنسي
@ar
name
Axel Le Cesne
@ast
Axel Le Cesne
@ca
Axel Le Cesne
@de
Axel Le Cesne
@en
Axel Le Cesne
@es
Axel Le Cesne
@fr
Axel Le Cesne
@it
Axel Le Cesne
@sl
type
label
Axel Le Cesne
@ast
Axel Le Cesne
@ca
Axel Le Cesne
@de
Axel Le Cesne
@en
Axel Le Cesne
@es
Axel Le Cesne
@fr
Axel Le Cesne
@it
Axel Le Cesne
@sl
prefLabel
Axel Le Cesne
@ast
Axel Le Cesne
@ca
Axel Le Cesne
@de
Axel Le Cesne
@en
Axel Le Cesne
@es
Axel Le Cesne
@fr
Axel Le Cesne
@it
Axel Le Cesne
@sl
P106
P19
P2038
Axel_Le_Cesne
P21
P27
P31
P3956
P4124
axel-le-cesne_79127
P569
1960-12-02T00:00:00Z